Corbus Pharmaceuticals Highlights Safe, Well-Tolerated CRB-913 Phase 1a Results With Emerging Evidence Of Weight Loss In Obesity
Benzinga Newsdesk 11 months ago
News
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at
- CRB-913 was safe and well-tolerated across all doses studied
- Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants
- A placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)
- A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026